Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | +6.70% | -5.91% | -50.71% |
05-20 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
05-17 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
Business Summary
Number of employees: 9
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Sapirstein
CEO | Chief Executive Officer | 63 | 19-10-07 |
Sarah Romano
DFI | Director of Finance/CFO | 44 | 22-02-28 |
Amy Chandler
CMP | Compliance Officer | 56 | - |
Martin Krusin
PRN | Corporate Officer/Principal | - | 13-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 17-03-02 | |
Ed Borkowski
BRD | Director/Board Member | 64 | 15-04-30 |
Alastair Riddell
BRD | Director/Board Member | 74 | 15-08-31 |
James Sapirstein
CEO | Chief Executive Officer | 63 | 19-10-07 |
Mary Coelho
BRD | Director/Board Member | 62 | 21-08-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,475,090 | 2,294,472 ( 92.70 %) | 0 | 92.70 % |
Company contact information
First Wave Biopharma, Inc.
777 Yamato Road Suite 502
33431, Boca Raton
+561 589 7020
http://www.firstwavebio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.71% | 4.8M | |
+35.14% | 51.07B | |
-7.43% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+11.63% | 26.35B | |
-17.77% | 19.46B | |
+40.52% | 13.58B | |
+30.70% | 12.46B | |
-3.41% | 11.75B |
- Stock Market
- Equities
- ENTO Stock
- Company Entero Therapeutics, Inc.